Idelalisib for treating chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA359
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Kandala, N‑B., Pink, J., Tsertsvadze, A., Sutcliffe, P., Court, R., Walewska, R., Clarke, A. Idelalisib Single Technology Appraisal – Idelalisib for relapsed chronic lymphocytic leukaemia [ID764]: A Single Technology Appraisal. Warwick Evidence, 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Gilead Sciences

II. Professional/expert and patient/carer groups:

  • Chronic Lymphocytic Leukaemia Support Association

  • Leukaemia CARE

  • Lymphoma Association

  • Association of Cancer Physicians

  • Cancer Research UK

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal College of Radiologists

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • GlaxoSmithKline (chlorambucil, ofatumumab)

  • Roche Products (rituximab, obinutuzumab)

  • National Cancer Research Institute

  • Warwick evidence

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on Idelalisib for previously treated chronic lymphocytic leukaemia by attending the initial Committee discussion and providing a written statement to the Committee. They are invited to comment on the ACD.

  • Professor Christopher Fegan, Director of Research and Development, nominated by Gilead – clinical expert

  • Dr Francesco Forconi, Consultant and Associate Professor, nominated by Royal College of Physicians – clinical expert

  • Nick York, Nominated by CLL Support Association – patient expert

  • Trisha Gardom, CLL Patient Advocate, nominated by CLL Support Association – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Gilead